23 results
ARS
2024 FY
ABSI
Absci Corp
23 Apr 24
Annual report to shareholders
4:10pm
products manufactured, processed or tested by them. Manufacturers and other parties involved in the drug supply chain for prescription drug products must … , the potential downstream adverse impacts are unknown but may include supply chain disruptions or delays. If any of our relationships with these third
424B5
ABSI
Absci Corp
28 Feb 24
Prospectus supplement for primary offering
8:34am
or our industry;
the potential impact of the ongoing COVID-19 pandemic, including supply chain issues arising from the pandemic and the emergence of new
424B5
ABSI
Absci Corp
27 Feb 24
Prospectus supplement for primary offering
4:40pm
pandemic, including supply chain issues arising from the pandemic and the emergence of new variants and sub variants of the virus on our business
424B5
ABSI
Absci Corp
16 Jun 23
Prospectus supplement for primary offering
4:45pm
pandemic, including supply chain issues arising from the pandemic and the emergence of new variants and sub variants of the virus on our business
ARS
0xdjrto43rnwztpt
28 Apr 23
Annual report to shareholders
12:00am
S-3
4ni9k9ipxp ru
24 Aug 22
Shelf registration
4:07pm
10-K
q6bc2a6
22 Mar 22
Annual report
5:20pm
10-Q
eg2 03mm1nc
7 Sep 21
Quarterly report
8:48am
424B4
mzayk
23 Jul 21
Prospectus supplement with pricing info
4:49pm
S-1/A
5wal3lha
8 Jul 21
IPO registration (amended)
5:04pm
S-1
2ghr8fwmb98
30 Jun 21
IPO registration
3:20pm
DRS/A
ed9m5yy0ro03xjwnp1
16 Jun 21
Draft registration statement (amended)
12:00am